Breast cancer is the most common cause of
cancer mortality in Western nations, with a terrible prognosis. Many studies show that
siRNA plays a role in the development of
tumors by acting as a
tumor suppressor and apoptosis inhibitor or both. siRNAs may be used as diagnostic and prognostic
biomarkers in
breast cancer. Antisurvivin
siRNA was chosen as a therapeutic target in
breast cancer treatment because it directly targets
survivin, an
inhibitor of apoptosis protein, that causes cell death. However,
siRNA-based treatment has significant limitations, including a lack of tissue selectivity, a lack of effective delivery mechanisms, low cellular absorption, and the possibility of systemic toxicity. To address some of these issues, we provide a
siRNA delivery method based on cationic
lipids. In the recent past, cationic
liposomes have displayed that they offer a remarkable perspective in proficient
siRNA delivery. The presence of a positive charge plays a vital role in firm extracellular
siRNA binding along with active intracellular
siRNA separation and low
biological adversities. Consequently, the methods for developing innovative cationic
lipids through rendering and utilization of appropriate positive charges would certainly be helpful for benign and effective
siRNA delivery. In the current study, an effort was made to synthesize a 3,4-dimethoxyaniline
lipid (DMA) to improve the effectiveness and protection of successful
siRNA delivery. DMA cationic
lipid successfully delivered
survivin siRNA that reduced the
survivin mRNA expression, indicating the possibility of utilizing
siRNA therapeutics for
breast cancer. It is expected that this innovative quaternary
amine-based
liposome can open up new avenues in the process of developing an easy and extensively used platform for
siRNA delivery. Cationic lipoplexes, a potential carrier system for
siRNA-based
therapies in the treatment of
breast cancer, were proven by our data.